发明名称 Haloalkyl heteroaryl benzamide compounds
摘要 A new class of haloalkyl heteroaryl benzamides is described. These compounds show strong activity against hepatitis viruses.
申请公布号 US9126992(B2) 申请公布日期 2015.09.08
申请号 US201414451637 申请日期 2014.08.05
申请人 Romark Laboratories, L.C. 发明人 Rossignol Jean-Francois;Semple J. Edward
分类号 A61K31/415;A61K31/4168;A61K31/4196;A61K31/421;A61K31/4245;A61K31/427;A61K31/433;C07D231/38;C07D233/38;C07D249/14;C07D261/14;C07D263/48;C07D271/07;C07D285/125;C07D275/03;C07D277/38;C07D417/12;C07D231/40;C07D231/44;C07D233/88;C07D233/90;C07D271/113;C07D277/46;C07D277/56;C07D285/08;C07D285/135;C07D403/06;C07D403/12;C07D405/12;C07D409/06;C07D413/12;C07D417/06;A61K31/454;A61K31/497;A61K31/506;A61K45/06;C07D401/12 主分类号 A61K31/415
代理机构 Foley & Lardner LLP 代理人 Foley & Lardner LLP
主权项 1. A pharmaceutical composition comprising a compound of Formula I:wherein: R1 through R5 and R10 are, independently, hydrogen, CN, NO2, F, Cl, Br, I, hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, cycloalkenyl, cycloalkenylalkyl, cycloalkenylalkenyl, cycloalkenylalkynyl, alkoxy, alkenyloxy, alkynyloxy, alkoxyalkyl, alkoxyalkenyl, alkoxyalkynyl, alkenyloxyalkyl, alkenyloxyalkenyl, alkenyloxyalkynyl, alkynyloxyalkyl, alkenyloxyalkenyl, alkenyloxyalkynyl, cycloalkoxy, cycloalkylalkoxy, cycloalkylalkenyloxy, cycloalkylalkynyloxy, cycloalkenyloxy, cycloalkenylalkoxy, cycloalkenylalkenyloxy, cycloalkenylalkynyloxy, alkoxyalkylamino, hydroxyalkyl, acyl, acyloxy, aroyloxy, arylalkanoyloxy, arylalkenoyloxy, heteroaroyloxy, heteroarylalkanoyloxy, heteroarylalkenoyloxy, alkoxycarbonyl, aryloxycarbonyl, arylalkoxycarbonyl, heteroaryloxycarbonyl, heteroarylalkoxycarbonyl, alkoxycarbonyloxy, carbamoyl, carbamoyloxy, alkylamino, dialkylamino, alkylaminoalkyl, amido, alkylamido, dialkylamido, haloalkyl, perhaloalkyl, perhaloalkoxy, alkylthio, alkylthioalkyl, alkylsulfonyl, alkylsulfonylalkyl, alkenylsulfonyl, alkynylsulfonyl, cycloalkylsulfonyl, cycloalkylalkylsulfonyl, cycloalkylsulfonylalkyl, cycloalkylalkylsulfonylalkyl, arylsulfonyl, arylalkylsulfonyl, arylalkenylsulfonyl, heteroarylsulfonyl, heteroarylalkylsulfonyl, heteroarylalkenylsulfonyl, alkylsulfonamido, N,N′-dialkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, sulfonamidoarylalkyl, sulfonamidoarylalkenyl, aryl, arylalkyl, aryloxy, arylalkoxy, arylthio, arylalkylthio, arylamino, arylalkylamino, arylalkenyl, arylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heteroaryloxy, heteroarylalkoxy, heteroarylamino, heteroarylalkylamino, heteroarylthio, heteroarylalkylthio, heteroarylalkylamino, heterocycloalkyl, heterocycloalkenyl, heterocycloalkoxy, or heterocycloalkenyloxy, any of which may be optionally substituted wherein R6 is selected from the group consisting of haloalkyl, perhaloalkyl, haloalkoxy, perhaloalkoxy, S(O)mC(R7R8)nCF3, and C(R7R8)nCF3; wherein W, X and Y are, independently, S, O, N, NR9 or CR10 where at least two of W, X, and Y are S, O, N, or NR9; wherein R7, R8, and R9 are, independently, hydrogen, fluoro, chloro, alkyl, perhaloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, or together with the atoms to which they are attached, may be joined to form an optionally substituted 4-to 8-membered heterocycloalkyl or an optionally substituted 3- to 8-membered cycloalkyl ring, any of which may be optionally substituted; m is an integer between 0 and 2; and n is an integer between 0 and 5;or a pharmaceutically acceptable salt or ester thereof,and a pharmaceutically acceptable carrier, wherein the composition comprises an effective amount of the compound for treating a viral pathogen.
地址 Tampa FL US